Sensorygen, Inc, 1228 Marengo Ave, South Pasadena, CA 91030, US

Genervon Biopharmaceuticals is a clinical-stage biopharmaceutical company based in Montebello, CA, dedicated to pioneering a new approach to drug development for complex neurological disorders. With a focus on multi-target drug discovery, Genervon has discovered a naturally occurring regulator of the human nervous system and developed a safe and well-tolerated peptide analog called GM6, which can penetrate the blood-brain barrier. GM6 has shown promising results in modulating biomarkers and defective pathways associated with neurodegenerative diseases, offering potential improvements in clinical outcomes for patients. With numerous worldwide patents, Genervon is currently planning late-stage clinical trials for GM6 in indications such as ALS, Parkinson's disease, Alzheimer's disease, and multiple sclerosis. Recognizing the urgent need for curative therapies, the company has dedicated the last two decades to research and development, employing a master regulatory approach to target the underlying pathophysiology and multiple pathways of neurodegenerative diseases and disorders. Genervon is actively seeking partnerships to advance GM6 from a development-stage drug candidate to a marketable therapy, providing much-needed help to the countless individuals affected by these debilitating conditions.Generated from the website